417 results on '"Hibi, Toshifumi"'
Search Results
2. Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis
3. 1139 UNITED STATES AND EUROPEAN PATIENT PERSPECTIVES ON THE IMPACT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS ON SEXUAL ACTIVITY: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY
4. Bile Acids Increase Levels of MicroRNAs 221 and 222, Leading to Degradation of CDX2 During Esophageal Carcinogenesis
5. Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results
6. Mo1079: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: IMPACT OF ULCERATIVE COLITIS SYMPTOMS ON HEALTH CARE PROFESSIONAL TREATMENT DECISIONS
7. Tu1506: CATEGORIZING THE RISK OF STEROID DEPENDENCE AFTER INITIAL STEROID THERAPY IN ULCERATIVE COLITIS: A NEW ANALYSIS WITH ARTIFICIAL NEURAL NETWORK
8. Sa1625: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: EXPERIENCE OF BOWEL URGENCY FOR PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS
9. Sa1627: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: PATIENT AND HEALTH CARE PROFESSIONAL PERSPECTIVES ON EXPERIENCE OF ULCERATIVE COLITIS SYMPTOMS
10. Su1766 OZANIMOD IS MORE EFFECTIVE IN ADVANCED THERAPY–NAIVE ULCERATIVE COLITIS PATIENTS WITH ENDOSCOPICALLY MODERATE VS SEVERE DISEASE REGARDLESS OF BASELINE PATIENT-REPORTED OUTCOMES OR PRIOR IMMUNOMODULATOR EXPOSURE
11. Sa1791 THE ASSOCIATION OF BOWEL URGENCY WITH DISTAL ENDOSCOPIC SEVERITY IN ULCERATIVE COLITIS.
12. 1080 EARLY TRANSPERINEAL ULTRASONOGRAPHY AS A PREDICTOR OF HISTOLOGICAL REMISSION IN ULCERATIVE COLITIS FOLLOWING ADVANCED THERAPY
13. Su1847 COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: IMPACT OF MODERATE-TO-SEVERE CROHN'S DISEASE SYMPTOMS ON HEALTH CARE PROFESSIONAL TREATMENT DECISIONS IN THE UNITED STATES AND EUROPE
14. Su1814 CLINICAL RELEVANCE OF BASELINE AND CHANGE IN URGENCY NUMERIC RATING SCALE SCORE FOR MIRIKIZUMAB TREATMENT FOR ULCERATIVE COLITIS
15. Su1795 OZANIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR ULCERATIVE COLITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN JAPAN (J-TRUE NORTH)
16. Su1865 COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: EUROPEAN AND US PATIENT AND HEALTH CARE PROFESSIONAL PERSPECTIVES ON THE BROAD IMPACT OF BOWEL URGENCY IN ULCERATIVE COLITIS
17. Su1859 COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: UNITED STATES AND EUROPEAN PATIENT PERSPECTIVES ON THE IMPACT OF MODERATE-TO-SEVERE CROHN'S DISEASE ON SEXUAL ACTIVITY
18. T-helper 17 and Interleukin-17–Producing Lymphoid Tissue Inducer-Like Cells Make Different Contributions to Colitis in Mice
19. CCL2-Induced Migration and SOCS3-Mediated Activation of Macrophages Are Involved in Cerulein-Induced Pancreatitis in Mice
20. Dysfunctional Gastric Emptying With Down-regulation of Muscle-Specific MicroRNAs in Helicobacter pylori-Infected Mice
21. Imbalance of NKp44 +NKp46 − and NKp44 −NKp46 + Natural Killer Cells in the Intestinal Mucosa of Patients With Crohn's Disease
22. Th1/Th17 Immune Response Is Induced by Mesenteric Lymph Node Dendritic Cells in Crohn's Disease
23. 648 EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
24. 132 EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE
25. Fr531 EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
26. Tu1765 SHEAR WAVE ELASTOGRAPHY PREDICTS SHORT-TERM RESPONSE TO INDUCTION THERAPY IN PATIENTS WITH CROHN'S DISEASE
27. 963 BOWEL URGENCY OUTCOMES ARE ASSOCIATED WITH IMPROVEMENT IN FATIGUE IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A POOLED ANALYSIS OF LUCENT-1 AND LUCENT-2 PHASE 3 TRIALS
28. Su1934 A DIRECT COMPARISON OF FECAL CALPROTECTIN, HIGH-SENSITIVITY C-REACTIVE PROTEIN, AND LEUCIN-RICH ALPHA-2 GLYCOPROTEIN IN DETECTING ACTIVITY OF SMALL BOWEL CROHN'S DISEASE
29. 633 THE FIRST PROSPECTIVE, MULTICENTER, RANDOMIZED CONTROLLED TRIAL ON DISCONTINUATION OF MAINTENANCE INFLIXIMAB IN ULCERATIVE COLITIS IN REMISSION; ENDOSCOPIC NORMALIZATION DOES NOT GUARANTEE SUCCESSFUL DISCONTINUATION
30. Tu1888 EARLY AND SUSTAINED IMPROVEMENT IN STOOL FREQUENCY AND RECTAL BLEEDING FOLLOWING 52 WEEKS OF MIRIKIZUMAB TREATMENT
31. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis
32. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease
33. Su1925 – Non-Adherence to Maintenance Medications is Common in Pregnant Ulcerative Colitis Patients and Contribute to Disease Flares and Adverse Pregnancy Outcomes-A Multicenter Prospective Study
34. 1005 – A Controlled Trial of Amiselimod, a Selective S1P Receptor Modulator in Crohn's Disease
35. Tu1838 – Does Switching Between 5-Aminosalicylates Affect Thiopurine Metabolism and Clinical Outcomes in Patient with Ulcerative Colitis?
36. 834 – Withdrawal of Thiopurines in Crohn's Disease Treated with Scheduled Adalimumab Maintenance : A Prospective Randomised Clinical Trial (DIAMOND2)
37. 1004 – Maintenence Treatment with Mirikizumab, a P19-Directed Il-23 Antibody: 52-Week Results in Patients with Moderately-Toseverely Active Ulcerative Colitis
38. 1003 – Efficacy and Safety of Mirikizumab (LY3074828) in a Phase 2 Study of Patients with Crohn's Disease
39. Tu1711 – Extended Treatment with Mirikizumab in Patients with Moderately-To-Severely Active Ulcerative Colitis: Results from a Phase 2 Trial
40. Tu1746 – A Phase 3 Study of Vedolizumab for Induction and Maintenance Therapy in Japanese Patients with Moderate to Severe Crohn's Disease
41. Interleukin 18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohn's disease
42. Mo1902 - Non-Adherence of IBD Medications and Disease Activity During Pregnancy and Pregnancy Outcomes -A Multicenter Study-
43. Sa1749 - Indigo Naturalis is Effective in Treatment-Refractory Patients with Ulcerative Colitis: Post-HOC Analysis from Indigo Study
44. Sa1768 - Clinical Factors Associated with Discontinuation of Combo or Monotherapy for Crohn's Disease: A Sub-Analysis of a Prospective Radomized Clinical Trial (Diamond Study)
45. Mo1863 - Multiple Ascending Dose, Open-Label, Phase 1/2 Study of E6011, an Anti-Fractalkine Monoclonal Antibody, to Investigate the Safety and Clinical Response in Patients with Crohn's Disease
46. Sa1700 - Incidence of Colorectal Cancer, Non-Melanoma Skin Cancers and Non-Hodgkin Lymphoma in Japanese Patients with Ulcerative Colitis - Results from an Analysis of a Large Nationwide Claims Database
47. Sa1751 - A Phase 3 Study of Vedolizumab for Induction and Maintenance Therapy in Japanese Patients with Moderately to Severely Active Ulcerative Colitis
48. Tu1316 - Eradication Therapy for Helicobacter Pylori is Safe for Patients with Inflammatory Bowel Disease
49. A Novel and Simple Regimen for an out of the Hospital Colon Capsule Endoscopy for the Management of Ulcerative Colitis
50. Combination Therapy with Adalimumab and Immunomodulators Decreases Incidence of Intestinal Resection in Crohn's Disease Patients Previously Treated with Infliximab: A Large, Multicenter Cohort Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.